Recent Press Releases

Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease

CAMBRIDGE, Mass., March 3, 2015 -- Blueprint Medicines today announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed...

Serenus Biotherapeutics Enters Equity Purchase and Acquisition Agreement With Ireland-Based Global Life Sciences Company

Malin Corporation plc to Invest up to $43 Million for up to a 76 Percent Stake in Specialty Pharmaceutical Focused on Africa SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA--(Marketwired - Mar 3,...

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

First submission of an investigational specific reversal agent to a novel oral anticoagulant (NOAC) for regulatory approval Boehringer Ingelheim pursues accelerated procedures with all three...

Neurons controlling appetite made from skin cells

Cells provide individualized model for studying obesity and testing treatments NEW YORK, NY (February 27, 2015) - Researchers have for the first time successfully converted adult human skin cells...

Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome Lyon, France, March 2, 2015 - Alizé Pharma, a company specialized in the development of drugs for the...

Chamaeleo Pharma Appoints Han Van 't Klooster as Vice President of Commercial Operations

Chamaeleo Pharma Appoints Han Van 't Klooster as Vice President of Commercial Operations Diegem, Belgium, March 2, 2015 / B3C newswire / - Chamaeleo Pharma NV, a Belgium-based oncology company,...

Shire Submits Application to the U.S. FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults

Shire Submits Application to the U.S. FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults Lexington, Mass. – March 2, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG)...

Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx

CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase...

Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer's Agitation, Depression and Other CNS Diseases

–– ALKS 7119 to Enter Clinic This Year; Joins Expanding CNS Pipeline Focused on Major Chronic Diseases –––– Company to Provide Update at Analyst and Investor...

GENENTA SCIENCE RAISES €6.2M IN FIRST TRANCHE OF SERIES A FUNDING

Genenta Science, a Milan, Italy-based biotech startup, raised €6.2m ($7.2m) in the first tranche of its Series A funding. Backers in the round, which is expected to close at €10m, included...

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif., March 2, 2015 -- Atara Biotherapeutics, Inc. (ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough...

Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan

Regenerative Medicine Partnership Focused on Development of Novel Stem Cell Therapy  CLEVELAND and TOKYO, March 2, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (ATHX) and Chugai Pharmaceutical Co.,...

U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

PRINCETON, N.J.--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA)...

Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors

-Focus on T Cell Response to Tumor-Specific Mutations- -Expansion of TCR and CAR Product Pipeline- SANTA MONICA, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (KITE), a clinical-stage...

Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need For Specialty Handling

Somerset, N.J. – Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today...

Liberia-U.S. Clinical Research Partnership Opens Trial to Test Ebola Treatments

Initial Study Will Evaluate Experimental Drug Cocktail ZMapp In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases (NIAID) today launched a clinical...

Glyconics Appoints Jeremy Williams as Non-Executive Director

Swansea, 24 February 2015 … Glyconics Limited has appointed Jeremy Williams as non-executive director, joining the Board of Directors. Glyconics, an innovative UK diagnostics company, is a...

Chiasma Announces Completion of $70 Million Series E Financing

Newton, Mass. and Jerusalem, Israel, February 27, 2015– Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition...

Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that it has appointed Mark Namchuk, Ph.D., as Senior Vice President of Research, Pharmaceutical and Nonclinical Development. Dr....

Charles River Laboratories Announces Planned Management Changes

Thomas F. Ackerman, Corporate Executive Vice President & Chief Financial Officer, Announces Planned Retirement in 2016 David R. Smith Will Transition to Chief Financial Officer Role Dr. Emily...